To explore the clinical features and efficacy evaluation of large b-cell lymphoma in old age.
The results of the analysis of the treatment of large b-cell lymphoma in old age were analyzed, and the treatment of large B cell lymphoma was provided.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
20
(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,epirubicin 50mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and six cycles are required. Efficacy was evaluated every two cycles.
The dose of the chemical was reduced by 20%,(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and one or two cycles are required. Efficacy was evaluated every two cycles. Subsequent (rituximab 375mg/m2 d0 ivgtt), oral cyclophosphamide .
Oncology Department of The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
RECRUITINGProgression-free survival
Progression-free survival
Time frame: up to end of follow-up-phase(approximately 24 months)
overall survival
overall survival
Time frame: up to the date of death (approximately 5 years)
disease control rate
disease control rate
Time frame: every 6 weeks,up to completion of treatment(approximately 18 weeks )]
objective remission rate
objective remission rate
Time frame: every 6 weeks,up to completion of treatment(approximately 18 weeks )]
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.